First Patient Dosed in Clinical Trial for Promising Dry AMD Therapy PST-611 – Patient Worthy

Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China

SHANGHAI--(BUSINESS WIRE)--Jul 13, 2025-

Golden Age Health secures rights to promote LX-101 gene therapy in China

Golden Age Health (GAH) has secured exclusive rights to commercialise and promote Innostellar Biotherapeutics’ first-in-class gene therapy candidate, LX-101, in mainland China. This ten-year Promotional Services Agreement leverages The post Golden Age Health secures rights to promote LX-101 gene therapy in China appeared first on Pharmaceutical Business review.

First Patient Dosed in Clinical Trial for Promising Dry AMD Therapy PST-611 – Patient Worthy

A new milestone has been reached in the search for effective treatments for dry age-related macular degeneration (AMD), as the first patient has now been dosed in a clinical trial testing PST-611, a novel therapeutic candidate. This development, reported by Pharma Times, marks an important step forward in the effort to address a significant unmet […]